MetaVia is trading at $1.75, up +5.42%, in pre-market; the reason for the move remains unclear.
- This compares with the September 29 close of $1.66. No clear company-specific announcement or credible report explaining the September 30 pre-market move was found.
- The latest company news surfaced was September 9 preclinical data on DA-1726, not a new catalyst for this session. Major indices in the supplied context are up less than 0.5%, offering no clear broad-market explanation.